CANbridge Pharmaceuticals Inc. (HKG:1228)

Market Cap	123.12M
Revenue (ttm)	90.56M
Net Income (ttm)	-471.02M
Shares Out	424.56M
EPS (ttm)	-1.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,002,000
Average Volume	11,136,730
Open	0.2850
Previous Close	0.2800
Day's Range	0.2700 - 0.3000
52-Week Range	0.0950 - 0.5000
Beta	-0.36
RSI	56.80
Earnings Date	Aug 27, 2025

About CANbridge Pharmaceuticals

CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy (ERT) for the treatment of Hunter syndrome; and Livmarli, an oral, minimally-absorbed, reversible ileal bile acid transporter inhibitor for the treatment of alagille syndrome and progressive familial intrahepatic cholestasis. It also develops CAN106, an anti-C5 mAb for paroxysmal nocturnal hemoglobinu...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 67
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1228

Financial Performance

In 2024, CANbridge Pharmaceuticals's revenue was 85.10 million, a decrease of -17.27% compared to the previous year's 102.87 million. Losses were -442.62 million, 16.8% more than in 2023.

Financial numbers in CNY